Pharming Group to Present at BioCapital Europe 2021
Conference attendancePharming Group today announces that its Chief Executive Officer, Sijmen de Vries, will present at BioCapital Europe 2021 at 10:30 CET on 11 March 2021
Pharming Group reports financial results for full year 2020
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended 31 December 2020.
Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program ‘navigateAPDS’ in US and Canada
Operational updatesNew program expected to improve access to genetic testing for activated PI3K delta syndrome (APDS), an ultra-rare immunodeficiency disease
Sign up now! Pharming Webinar: Full year results
WebinarsPharming’s CEO Sijmen de Vries and CFO Jeroen Wakkerman look back at 2020 and the recently published full year financial results.
Pharming Group announces ADSs admitted to trade on Nasdaq under the symbol “PHAR”
Financial updatesPharming Group announces that, effective today, its American Depositary Shares (“ADSs”) have been admitted for listing on the Nasdaq Global Market (“Nasdaq”) under the symbol “PHAR” and will begin trading tomorrow; Wednesday 23 December. Each ADS represents 10 of the Company’s ordinary shares of €0.01 nominal value (“Ordinary Shares”).
Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs
Financial updatesCosts for conversion of Ordinary Shares into ADS’s waived by JP Morgan Chase for initial four weeks after today
Pharming Reports on Extraordinary General Meeting of Shareholders
Financial updatesPharming Group N.V. announces that at its Extraordinary General Meeting of shareholders (EGM), held today, all proposals were approved. As a result, the one-tier board structure has become effective, and Barbara Yanni and Mark Pykett have been appointed as non-executive board members.
Pharming announces enrolment of first patient in US clinical trial for the treatment of COVID-19 with RUCONEST®
Clinical trialsPharming Group N.V. announces that the first patient has been enrolled in a randomized, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalized with confirmed COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infections at the Valley Hospital in Ridgewood, New Jersey in the United States.
Sign up for Pharming’s EGM 2020 Webinar
WebinarsPharming Group N.V. will hold it’s 2020 Extraordinary General Meeting (EGM) on 11 December 2020 at 14:00 CET.
Pharming Group Publicly Files Registration Statement with the U.S. SEC to Facilitate Listing of ADSs Representing Ordinary Shares on Nasdaq Global Market
Financial updatesPharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with a proposed listing of American Depositary Shares ("ADSs") representing the Company's ordinary shares of nominal value €0.01 each ("Ordinary Shares") on the Nasdaq Global Market ("Nasdaq").